William Blair Issues Pessimistic Outlook for BMRN Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Investment analysts at William Blair cut their Q1 2025 earnings per share estimates for BioMarin Pharmaceutical in a research report issued on Monday, April 14th. William Blair analyst S. Corwin now expects that the biotechnology company will post earnings of $0.77 per share for the quarter, down from their previous estimate of $0.85. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share. William Blair also issued estimates for BioMarin Pharmaceutical’s FY2025 earnings at $3.47 EPS and FY2026 earnings at $4.33 EPS.

BMRN has been the topic of several other reports. Wedbush restated an “outperform” rating and set a $94.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Piper Sandler boosted their target price on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an “overweight” rating in a report on Thursday, February 20th. Oppenheimer raised shares of BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 price target for the company in a research note on Monday, February 24th. Cantor Fitzgerald reissued an “overweight” rating and issued a $90.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Finally, UBS Group lifted their target price on BioMarin Pharmaceutical from $109.00 to $113.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. Seven research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $94.00.

BioMarin Pharmaceutical Trading Up 0.6 %

Shares of BMRN stock opened at $59.17 on Thursday. BioMarin Pharmaceutical has a twelve month low of $52.93 and a twelve month high of $94.85. The stock’s fifty day simple moving average is $66.83 and its 200 day simple moving average is $66.35. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $11.29 billion, a P/E ratio of 26.90, a P/E/G ratio of 0.61 and a beta of 0.30.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, beating analysts’ consensus estimates of $0.54 by $0.18. The firm had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BMRN. Norges Bank bought a new position in BioMarin Pharmaceutical in the 4th quarter valued at about $234,645,000. Capital Research Global Investors raised its stake in shares of BioMarin Pharmaceutical by 23.8% in the fourth quarter. Capital Research Global Investors now owns 12,991,772 shares of the biotechnology company’s stock worth $853,944,000 after purchasing an additional 2,496,817 shares during the last quarter. Soleus Capital Management L.P. bought a new position in shares of BioMarin Pharmaceutical in the fourth quarter valued at approximately $65,822,000. Dodge & Cox boosted its position in shares of BioMarin Pharmaceutical by 6.1% during the fourth quarter. Dodge & Cox now owns 14,746,235 shares of the biotechnology company’s stock valued at $969,270,000 after buying an additional 847,917 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in BioMarin Pharmaceutical by 114.5% during the fourth quarter. AQR Capital Management LLC now owns 1,283,599 shares of the biotechnology company’s stock worth $84,371,000 after buying an additional 685,099 shares in the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,344 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $68.38, for a total transaction of $91,902.72. Following the transaction, the chief accounting officer now owns 13,105 shares in the company, valued at approximately $896,119.90. This represents a 9.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.85% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.